OTC deficiency is a rare genetic condition and the most prevalent urea cycle disorder. Newborns with neonatal onset OTC deficiency exhibit hyperammonemia symptoms shortly after birth, including ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

An ELRIG webinar has explored how cell-based screening supports drug discovery, from early target validation to advanced ...

When we hear that a person has quirks, we expect to be charmed. But when we hear that a cell-based assay has quirks, we expect to be frustrated. Quirks in cell-based assays tend to complicate drug ...

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect® Fc Fusion, a novel assay designed to ...

A new Armatus publication summarizes a novel potency assay platform to advance gene silencing therapies for rare neuromuscular diseases.

Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining ...

In the ever-evolving landscape of biomedical research, the need for reliable, consistent, and ready-to-use cell models has never been more critical. ATCC, a leading provider of biological materials, ...

BURLINGAME, CA, UNITED STATES, February 16, 2026 /EINPresswire.com/ -- The Global Business Landscape is being reshaped by rapid innovation, rising investment and ...